KSC · 096760.KS
JW Holdings Corporation
₩3,965-₩35 (-0.88%)
JW Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 16.0% below the high.
Loading market information…
KSC · 009290.KS · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Kwang Dong Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 51.25% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Kwang Dong Pharmaceutical Co., Ltd.’s forward annual dividend is ₩100 per share, paid annual. The forward yield is 1.6% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Kwang Dong Pharmaceutical Co., Ltd.’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kwang Dong Pharmaceutical Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in Seoul, South Korea, in 1963, Kwang Dong Pharmaceutical Co., Ltd. functions as a diversified healthcare enterprise. The company is actively involved in the development and distribution of an extensive range of pharmaceutical products. This portfolio includes various over-the-counter (OTC) remedies addressing common ailments such as coughs and colds, eye care, liver conditions, mineral deficiencies, vitamin supplementation, circulatory health, and general wellness tonics. Complementing these are its prescription-only (ETC) medicines, which encompass treatments for a broad spectrum of medical needs, including diabetes, cardiovascular disorders, metabolic imbalances, digestive issues, immune system modulation, obesity, genitourinary and anal conditions, neurological and psychiatric disorders, pain and inflammation, infections, and anti-cancer therapies. Beyond pharmaceuticals, Kwang Dong offers health supplements and a diverse selection of beverages, ranging from general consumer drinks to functional and traditional health-focused options. The company also extends its operations to include the management of hospitals and facilitates widespread product distribution through various retail and wholesale channels, including discount stores, television home shopping, and online e-commerce platforms. Furthermore, Kwang Dong Pharmaceutical acts as a comprehensive MRO (Maintenance, Repair, and Operations) service provider, specializing in the procurement of raw materials, intermediate goods, and industrial consumables, with services extending to construction and international sourcing.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:37 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q3 2024 | Nov 14, 2024 | ₩220 | ₩424.59B+35,185.38% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩3,965-₩35 (-0.88%)
JW Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 16.0% below the high.
₩19,250-₩120 (-0.62%)
Samjin Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.68% below the high.
₩9,370+₩10 (+0.11%)
REYON Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.02% below the high.
₩35,600+₩200 (+0.56%)
Chong Kun Dang Holdings Corp.’s quoted price sits in the lower half of its reported 52-week range, 35.97% below the high.
₩7,650-₩40 (-0.52%)
Samil Pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 40.51% below the high.
₩10,510-₩80 (-0.76%)
JW Lifescience Corporation’s quoted price sits in the lower half of its reported 52-week range, 32.54% below the high.
₩8,070-₩160 (-1.94%)
Hana Pharm Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.3% below the high.
₩5,090-₩220 (-4.14%)
AptaBio Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.26% below the high.
